Cliff Asness’s Flexion Therapeutics, Inc. FLXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-118,437
| Closed | -$722K | – | 2340 |
|
|
2021
Q3 | $722K | Buy |
118,437
+103,995
| +720% | +$648K | ﹤0.01% | 1722 |
|
|
2021
Q2 | $119K | Buy |
+14,442
| New | +$123K | ﹤0.01% | 2181 |
|
|
2020
Q4 | – | Sell |
-18,736
| Closed | -$195K | – | 2295 |
|
|
2020
Q3 | $195K | Sell |
18,736
-11,546
| -38% | -$141K | ﹤0.01% | 2065 |
|
|
2020
Q2 | $398K | Buy |
30,282
+17,395
| +135% | +$180K | ﹤0.01% | 1823 |
|
|
2020
Q1 | $101K | Buy |
+12,887
| New | +$194K | ﹤0.01% | 1964 |
|
|
2017
Q3 | – | Sell |
-18,347
| Closed | -$371K | – | 2315 |
|
|
2017
Q2 | $371K | Buy |
+18,347
| New | +$382K | ﹤0.01% | 1983 |
|
|
2016
Q1 | – | Sell |
-15,068
| Closed | -$290K | – | 2312 |
|
|
2015
Q4 | $290K | Sell |
15,068
-35,246
| -70% | -$612K | ﹤0.01% | 2045 |
|
|
2015
Q3 | $748K | Buy |
50,314
+1,138
| +2% | +$26.7K | ﹤0.01% | 1575 |
|
|
2015
Q2 | $1.08M | Buy |
+49,176
| New | +$992K | ﹤0.01% | 1456 |
|
Cliff Asness's FLXN Position: Q4 2021 in Review
Cliff Asness sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 118,437 shares — an estimated $722K sold.
Cliff Asness first reported a position in FLXN in Q2 2015 and held it in 9 quarters. The position peaked at $1.08M in Q2 2015. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.
- Cliff Asness reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
- Cliff Asness sold 118,437 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $722K.
- Cliff Asness first reported a position in Flexion Therapeutics, Inc. in Q2 2015 and held it in 9 quarters.
- Cliff Asness's Flexion Therapeutics, Inc. position peaked at $1.08M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.
Based on AQR Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.